Read + Share
Du Y, Chen Y, Wang Y, Chen J, et al. HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes
Osimertinib-Resistant EGFR Triple Mutations. Mol Cancer Ther 2022;21:1060-1066.
PMID: 35499406
|
 |
|
Du Y, Chen Y, Wang Y, Chen J, et al. HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes
Osimertinib-Resistant EGFR Triple Mutations. Mol Cancer Ther 2022;21:1060-1066.
PMID: 35499406
|
|
|
|